Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.

doi:10.3390/ijms17020237

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.

International journal of molecular sciences - 15 Feb 2016

Sin Thomas K, Wang Fengfeng, Meng Fei, Wong S C Cesar, Cho William C S, Siu Parco M, Chan Lawrence W C, Yung Benjamin Y M

Abstract excerpt

Non-small cell lung cancer (NSCLC) represents about 85% of the reported cases of lung cancer. Acquired resistance to targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is not uncommon. It is thus vital to explore novel strategies to r...

Topics

Animals
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Biological Products
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Drug Resistance, Neoplasm
Drug Synergism
ErbB Receptors
Gefitinib
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
MicroRNAs

Source

Open in PubMed Open full text

Identifiers

PMID: 26891293
DOI: 10.3390/ijms17020237
PMCID: PMC4783968

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-26891293-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutation

Protein Kinase Inhibitors

Quinazolines